Continuing Education Activity

This continuing education activity reviews the interpretation and clinical application of liver biochemistries in adults. Although these tests are among the most frequently ordered laboratory studies, mild or isolated abnormalities are often transient, extrahepatic, or clinically insignificant, while normal results do not exclude clinically meaningful liver disease. Misinterpretation can lead to delayed diagnosis, unnecessary testing, missed fibrosis risk, and inappropriate referral patterns. This activity addresses the practice gap by providing a structured framework for evaluating liver test patterns, assessing preanalytical and biological sources of variation, distinguishing hepatocellular from cholestatic abnormalities, and recognizing the significance of bilirubin, albumin, and coagulation findings in severity assessment. Participants gain practical strategies for targeted history taking, medication review, risk-based follow-up, noninvasive fibrosis assessment, and timely interdisciplinary collaboration to support accurate diagnosis, efficient management, and improved patient outcomes.

Objectives:

• Identify patterns of liver biochemistry abnormalities that suggest hepatocellular injury, cholestatic disease, isolated hyperbilirubinemia, or impaired hepatic synthetic reserve.
• Differentiate transient or clinically insignificant abnormalities from persistent findings that warrant targeted laboratory evaluation, imaging, fibrosis risk assessment, or specialist referral.
• Assess preanalytical, analytical, and biological factors that may interfere with liver biochemistry results and incorporate those factors into clinical interpretation.
• Collaborate with nurses, pharmacists, laboratory professionals, and specialists to improve medication reconciliation, diagnostic evaluation, referral decisions, and ongoing care for patients with abnormal liver biochemistries.

Access free multiple choice questions on this topic.

Introduction

The liver, located in the right upper quadrant beneath the diaphragm, performs essential roles in metabolism, digestion, detoxification, and the synthesis of proteins and bile constituents. Liver-related laboratory panels are commonly ordered in both symptomatic and asymptomatic individuals to screen for hepatobiliary disease, identify injury patterns, and monitor disease activity or treatment response. The term liver function tests is an imprecise label for what most clinicians order.

The American College of Gastroenterology (ACG) recommends using the term liver chemistries because many components of the panel reflect liver injury or cholestasis rather than liver function itself. Most panels include alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (markers of hepatocellular injury), alkaline phosphatase with gamma-glutamyl transferase/5′-nucleotidase (markers supporting a cholestatic or hepatobiliary source for an elevated alkaline phosphatase result), bilirubin, and markers that better reflect hepatic synthetic performance, such as prothrombin time and international normalized ratio (PT/INR) and albumin. Even these synthetic markers are not liver-specific, as albumin is influenced by nutrition, inflammation, and renal and gastrointestinal protein loss, and PT/INR can be altered by vitamin K status and anticoagulants.

Interpreting normal results also requires understanding the definition of normality in laboratory medicine. Most laboratory reference intervals are statistically defined, often as the central approximately 95% of a reference population, so a minority of healthy individuals will fall outside the interval by definition. Additionally, reference limits vary by laboratory methodology and by patient factors, including sex, age, body composition, and cardiometabolic risk.

Contemporary work has reexamined the upper reference limits for alanine aminotransferase using more rigorously defined healthy cohorts and has proposed lower sex-specific upper limits in some settings. Normal liver chemistries also do not exclude clinically meaningful liver disease. Metabolic dysfunction–associated steatotic liver disease (MASLD) and even fibrosis may be present despite aminotransferase results within the reported reference range; therefore, interpretation should integrate the clinical context, risk factors, and, when indicated, noninvasive fibrosis assessment rather than relying on a normal liver chemistry panel result to rule out disease.[1][2][3][4]

Etiology and Epidemiology

Abnormal liver function tests are common in clinical practice, with mildly elevated ALT and AST levels observed in approximately 10% to 20% of the general population, supporting an initial approach of verifying persistence before comprehensive evaluation. The most common causes of these abnormalities are MASLD, previously known as nonalcoholic fatty liver disease, and alcohol-related liver disease. The approximate prevalence rates of various causes of undifferentiated liver disease in the United States and United Kingdom populations are listed below:

• Nonalcoholic fatty liver disease: 41%
• Alcohol-related liver disease: 13.5%
• Hepatitis C: 7%
• Drug-induced liver injury: 4.4%
• Autoimmune hepatitis: 1.8%
• Hepatitis B: 0.96%
• Primary biliary cholangitis: 0.2%
• Primary sclerosing cholangitis: 0.2%
• Wilson disease: 0.16%
• α₁-antitrypsin deficiency: 0.16% [5]

Extrahepatic conditions, such as thyroid disorders, celiac disease, muscle disorders (eg, rhabdomyolysis), and heart failure, can also lead to abnormal liver chemistry results. Clinicians should consider these conditions, especially when initial evaluations do not provide clear results. Epidemiologically, the burden of abnormal liver chemistry results is shifting toward metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease. At the same time, the prevalence of viral hepatitis has decreased because of improved treatment.

The American College of Gastroenterology recommends a systematic approach to assessing abnormal liver chemistries. This approach includes obtaining a comprehensive medical history, focusing on alcohol use, medications, and risk factors for viral hepatitis. The evaluation also includes a comprehensive physical examination, targeted laboratory testing, and imaging studies to identify the underlying cause.

Elevated liver function tests are found in approximately 8% of the general population, and up to 30% of asymptomatic elevations are transient, resolving in 3 weeks. Therefore, caution should be exercised when interpreting these results to avoid unnecessary testing.[6] A borderline elevation of AST or ALT is defined as less than 2 times the upper limit of normal, a mild elevation as 2 to 5 times the upper limit of normal, a moderate elevation as 5 to 15 times the upper limit of normal, a severe elevation as greater than 15 times the upper limit of normal, and a massive elevation as greater than 10,000 IU/L. The degree of AST and ALT elevation varies depending on the cause of hepatocellular injury.[7]

Etiology Based on Patterns of Elevation in Liver Function Tests

Hepatocellular pattern 

Elevated aminotransferase levels are disproportionately higher than alkaline phosphatase levels in the hepatocellular pattern.

• ALT-predominant causes include acute or chronic viral hepatitis, steatohepatitis, acute Budd-Chiari syndrome, ischemic hepatitis, autoimmune conditions, hemochromatosis, medications and toxins, α₁-antitrypsin deficiency, Wilson disease, and celiac disease.
• AST-predominant causes include alcohol-related liver disease, steatohepatitis, cirrhosis, and nonhepatic causes (eg, hemolysis, myopathy, thyroid disease, and exercise).

Cholestatic pattern

Elevated alkaline phosphatase and gamma-glutamyl transferase (GGT) levels with disproportionately high bilirubin levels compared to AST and ALT levels.

• Hepatobiliary causes include bile duct obstruction, primary biliary cholangitis, primary sclerosing cholangitis, medication-induced liver injury, infiltrative liver diseases (such as sarcoidosis, amyloidosis, and lymphoma), cystic fibrosis, hepatic metastasis, and cholestasis.
• Nonhepatic causes include bone disease, pregnancy, chronic renal failure, lymphoma or other malignant neoplasms, congestive heart failure, normal growth in children, infections, or inflammation.[8][9][10]

Pathophysiology

The routine liver panel is better understood as a set of liver biochemistries that sample different physiologic processes rather than a single measure of hepatic function. Individual tests reflect hepatocellular integrity, bile formation and flow, bilirubin handling, or hepatic synthetic capacity, and these domains do not change in parallel in all diseases. This difference explains why marked elevations in aminotransferases may occur with preserved albumin and coagulation parameters, whereas advanced chronic liver disease may be present with only modest enzyme abnormalities. The pathophysiology is therefore best interpreted in terms of patterns and trajectories rather than isolated values.

Hepatocellular Laboratory Examination

Aspartate aminotransferase and ALT are intracellular enzymes released into the circulation when hepatocytes are injured or when membrane permeability increases. Their serum levels reflect a dynamic balance between release from injured tissue and clearance from blood, rather than a direct measurement of viable hepatocyte mass. ALT is more liver-specific and largely cytosolic, making ALT more specific for hepatocellular injury in most clinical settings. AST is less specific because AST is present in multiple tissues, including skeletal muscle, myocardium, kidney, brain, leukocytes, and erythrocytes, and AST exists in both cytosolic and mitochondrial forms. This distribution contributes to common clinical patterns, including AST-predominant elevations in some alcohol-related and severe necroinflammatory states, and accounts for extrahepatic causes of AST elevation.

The magnitude of aminotransferase elevation does not reliably correlate with histologic severity or prognosis across all conditions. In acute injury, very high values may indicate extensive hepatocellular damage, whereas lower values do not exclude clinically important disease. Conversely, a decline in AST and ALT may indicate recovery, yet in acute liver failure, a falling aminotransferase result can coincide with worsening hepatic reserve when bilirubin rises, and PT and INR values become prolonged. This apparent paradox reflects the fact that aminotransferases are injury markers rather than direct measures of hepatic functional capacity.

Interpretation of aminotransferase results also depends on how normal is defined. Reference intervals are influenced by sex, body composition, metabolic risk, laboratory methodology, and the characteristics of the population used to derive the interval. Individuals with unrecognized steatotic liver disease may be included in reference populations, thereby widening the apparent reference range. For this reason, values near the upper limit of normal require clinical judgment, and results within the reference range should not be assumed to represent the absence of liver disease in all patients.

Cholestasis Laboratory Examination

Cholestatic biochemistry reflects a different pathophysiologic process and should be considered independently from aminotransferase-based hepatocellular injury. Alkaline phosphatase (ALP) is concentrated in the canalicular membrane of hepatocytes and bile duct epithelium, and ALP is also produced in bone, placenta, and intestine. In cholestatic states, ALP elevation reflects altered canalicular transport and enzyme induction associated with impaired bile flow and retention of biliary constituents, rather than simple passive leakage alone. This mechanism explains why cholestatic disorders may produce disproportionate elevations in ALP even when aminotransferase results are only mildly abnormal.

Gamma-glutamyl transferase and, where available, 5′-nucleotidase help localize an elevated ALP result to the hepatobiliary system. Because ALP is not liver-specific, a concordant elevation of GGT increases the likelihood of a hepatic or biliary source. In contrast, a normal GGT result raises the possibility of a nonhepatic source, such as bone. GGT is itself imperfect because alcohol, medications, and other conditions may induce it. Still, it remains clinically useful as a localization marker when interpreted in the context of the rest of the panel.

Bilirubin abnormalities arise from disturbances at any point in bilirubin handling, including overproduction, hepatic uptake, conjugation, canalicular excretion, or biliary drainage. Total bilirubin, therefore, represents the net effect of multiple processes, and hyperbilirubinemia can reflect hepatocellular injury, cholestasis, hemolysis, inherited disorders of conjugation, or mixed mechanisms. Fractionation into direct and indirect components remains clinically useful, particularly in distinguishing predominantly unconjugated from conjugated hyperbilirubinemia, but interpretation is influenced by assay method. The measured direct fraction is partly method-defined, and analytical interference from lipid, drug, or bilirubin fractions (such as delta bilirubin) can affect the results, especially at low concentrations.

Synthetic Function Tests

Albumin, prothrombin time, and INR fall into a different physiologic category than AST, ALT, ALP, and GGT. Clinicians often group these tests into liver panels, although they are better interpreted as contextual indicators of synthetic reserve than as direct liver-specific markers. Albumin concentration changes relatively slowly because of its long half-life and is strongly influenced by inflammation, nutritional status, renal or gastrointestinal protein loss, and volume status. Prothrombin time and INR may change more rapidly in impaired hepatic synthesis because clotting factor half-lives are shorter, but they are also affected by vitamin K deficiency, anticoagulants, malabsorption, and systemic coagulopathy. Their clinical value is substantial, but their interpretation requires attention to competing nonhepatic influences.

Serological Testing

Liver-related autoantibodies are crucial for accurate diagnosis and classification of autoimmune liver diseases, namely, autoimmune hepatitis type 1 (AIH-1), autoimmune hepatitis type 2 (AIH-2), primary biliary cholangitis (PBC), and the sclerosing cholangitis variants in adults and children. AIH-1 is specified by antinuclear antibody and anti–smooth muscle antibody. AIH-2 is specified by antibody to liver kidney microsomal antigen type 1 (anti-LKM1) and anti-liver cytosol type 1.

Smooth muscle antibody, antinuclear antibody ANA, and anti-LKM1 antibodies can be present in de novo AIH following liver transplant.[11] PBC is characterized by antimitochondrial antibodies that react with enzymes of the 2-oxo-acid dehydrogenase complexes, chiefly the pyruvate dehydrogenase complex E2 subunit (PDC-E2), and by a disease-specific antinuclear antibody that mainly reacts with nuclear pore gp210 and nuclear body sp100. Sclerosing cholangitis presents in at least 2 variants. The first variant, classic primary sclerosing cholangitis, mostly affects adult men, and the only nonspecific serological reactivity is an atypical perinuclear antineutrophil cytoplasmic antibody (p-ANCA), also termed perinuclear antineutrophil nuclear antibodies. The second variant is childhood autoimmune sclerosing cholangitis, which has serological features resembling those of type 1 AIH.[12]

Secondary Biochemical Liver Testing

Alpha-fetoprotein measurements are used as tumor markers for the detection and monitoring of primary hepatocellular cancers, such as hepatoblastoma and hepatocellular carcinoma. Hepatoblasts produce α₁-fetoprotein, which is why α₁-fetoprotein levels increase in the regenerating liver, particularly in chronic viral hepatitis.[13] Carbohydrate-deficient transferrin is a high-specificity test for detecting excess alcohol intake as a cause of liver damage. The carbohydrate antigen 19-9 is useful for monitoring disease activity in primary sclerosing cholangitis, which often progresses to bile duct tumors or cholangiocarcinoma.[14] Measurement of serum ferritin can be useful in identifying hemochromatosis, but ferritin is a positive acute-phase reactant, so it is elevated in many illnesses and is released from damaged hepatocytes in acute hepatic failure.[15]

Other enzymes, such as lactate dehydrogenase, glutamate dehydrogenase, isocitrate dehydrogenase, and sorbitol dehydrogenase, offer additional insights into patterns of cellular injury and have been studied in selected contexts, including ischemic and drug-induced liver injury. However, these enzymes have not displaced standard liver biochemistries in routine care because of limitations in sensitivity, specificity, availability, or practicality. Their relevance in a modern review lies mainly in illustrating that hepatocellular injury is biologically heterogeneous and that biomarker performance depends on the compartment and mechanism of injury being measured.

A normal liver panel result usually indicates the absence of a strong biochemical signal of hepatocellular injury, significant cholestatic stress, or overt synthetic failure at the time of testing. A normal liver panel result does not establish normal liver histology, exclude fibrosis, or rule out compensated chronic liver disease. This distinction is particularly important in MASLD, where steatosis and fibrosis may be present despite aminotransferase values within standard reference ranges. In that setting, normal results are best understood as biochemically quiet rather than definitively disease-free.[3][4][16][17][18][19][20]

Specimen Requirements and Procedure

Most of the time, serum is used to test for AST, ALT, ALP, GGT, bilirubin, albumin, and total protein. PT/INR should be collected in a separate coagulation tube and processed through the coagulation laboratory workflow. PT and INR require different specimen collection methods than chemical tests.

Correct specimen handling before analysis is crucial because specimen quality can substantially impact results. To avoid hemolysis and other artifacts, clinicians and laboratory personnel should use standard phlebotomy techniques, label samples correctly, transfer them promptly, and centrifuge and separate them promptly. If testing is delayed, samples should be stored according to the assay's needs, usually refrigerated for short delays and frozen for longer ones, and they should not be frozen and thawed repeatedly.

When testing for bilirubin, samples should be processed right away and kept out of direct sunlight whenever possible. Bilirubin measurements depend on the method used and can be altered by specimen handling. Several labs also use hemolysis, icterus, and lipemia indices to identify samples that may yield inaccurate results.[21][22]

Testing Procedures

Liver chemistry tests are performed on semiautomatic or fully automated analyzers that operate on the principle of photometry. Photometry is the measurement of light absorbed in the ultraviolet, visible, and infrared ranges. This measurement is used to determine the concentration of an analyte in a solution.

Photometers use a specific light source and detectors that convert light passed through a sample solution into a proportional electrical signal. These detectors may be photodiodes, photoresistors, or photomultipliers. Photometry uses the Beer–Lambert law to calculate coefficients from transmittance measurements. A correlation between absorbance and analyte concentration is then established by a test-specific calibration function to achieve highly accurate measurements.[23]

Interfering Factors

Interference in liver chemistries can arise from true analytical effects on the assay, from preanalytical variables related to specimen collection and timing, or from patient-related biological factors that alter measured values without primary hepatobiliary disease. In routine chemistry testing, the most frequent specimen integrity problems are hemolysis, icterus, and lipemia (HIL). Modern analyzers often automatically estimate HIL indices, but the effect is assay- and platform-specific; therefore, laboratories should rely on instrument-validated thresholds rather than generalized assumptions.

Hemolysis may produce falsely abnormal results through spectral interference and by the release of intracellular constituents. Hemolysis is particularly relevant for colorimetric or spectrophotometric methods that read at wavelengths affected by hemoglobin absorbance. In addition, hemolysis may spuriously increase certain analytes (eg, AST) because erythrocytes contain intracellular enzymes, whereas certain assays, including some alkaline phosphatase methods, may exhibit negative interference, depending on reagent chemistry and analyzer design. Icterus (bilirubin) can interfere both spectrophotometrically and chemically, and the degree and direction of the effect may differ across assays and between unconjugated and conjugated bilirubin-rich samples.

Lipemia causes interference through light scattering, sample nonhomogeneity, and reagent-analyte partitioning effects. Methods that depend on reduced nicotinamide adenine dinucleotide phosphate absorbance around 340 nm are especially vulnerable. Useful results from recent interference studies indicate that native lipemic specimens do not always behave as samples spiked with intravenous lipid emulsions (eg, Intralipid and SMOFlipid [Fresenius Kabi]). Consequently, manufacturer claims or in-house validation based only on lipid-emulsion spiking may not fully predict interference in patient samples. Laboratories should have a defined protocol for handling lipemic specimens that may include repeating testing after fasting when appropriate, using validated ultracentrifugation or clearing methods, or using alternative methods.

Beyond specimen quality, biological and preanalytical variation can meaningfully affect the interpretation of aminotransferase and cholestatic enzyme results. ALT and AST levels vary with sex, body habitus, sampling timing, recent exercise, fasting status, and intercurrent illness; diurnal and other physiologic rhythms also contribute to within-person variation. These influences do not invalidate testing, but they can shift values enough to complicate the interpretation of borderline abnormalities and trends. Standardizing collection conditions, including the time of day, fasting status when needed, and repeat testing under similar conditions, improves comparability.

Medication-related issues should also be interpreted carefully. Drugs may cause true liver injury, which is a clinical diagnosis, not an assay artifact, and some drugs may also cause assay interference. For example, older concerns about metronidazole interfering with spectrophotometric chemistry assays have not been reproduced on some contemporary analyzer platforms, emphasizing that interference claims are method-specific and should not be generalized across systems. In addition, persistent isolated AST elevation may occasionally reflect macro-AST, a benign macroenzyme phenomenon, which can trigger extensive unnecessary evaluation if not considered.

Age and physiologic state also matter. ALP levels are typically elevated in children and adolescents due to bone growth and commonly rise in pregnancy (especially in late gestation) due to placental isoenzyme contribution. These increases should not be misclassified as hepatobiliary disease without corroborating findings. When an isolated elevation in ALP is unexpected, repeat testing (often after fasting) and confirmation of hepatic origin with GGT or ALP isoenzyme testing can reduce misinterpretation.[24][25][26]

Results, Reporting, and Critical Findings

The results of liver chemistries should correlate with the initial findings in a complete patient history and physical examination. A thorough review should include important questions regarding the patient's age and past medical history, including diabetes mellitus, obesity, hyperlipidemia, inflammatory bowel disease, celiac sprue, thyroid disorders, autoimmune hepatitis, acquired muscle disorders, alcohol use disorder, medication use, toxin exposure, and family history of genetic liver conditions, including Wilson disease, α₁-antitrypsin deficiency, and hereditary hemochromatosis.[27]

A review of systems should also include signs and symptoms of chronic liver disease, such as jaundice, ascites, peripheral edema, hepatosplenomegaly, gynecomastia, testicular hypotrophy, muscle wasting, encephalopathy, pruritus, and gastrointestinal bleeding. Other tests that help determine the cause of elevated transaminase levels include fasting lipid levels, hemoglobin A1c, fasting blood glucose, complete blood cell count with platelets, complete metabolic panel, iron studies, hepatitis C antibody, and hepatitis B surface antigen. Reference ranges for liver chemistries vary by laboratory. Additionally, normal reference ranges vary between women and men and may be higher for patients with a higher body mass index.[23] A patient's blood test results should be interpreted using the laboratory's reference values. Each laboratory should establish its own reference interval based on its methodology. Typical reference ranges include:

• Alanine aminotransferase: 4 to 36 IU/L
• Aspartate aminotransferase: 5 to 30 IU/L
• Alkaline phosphatase: 30 to 120 IU/L
• Gamma-glutamyltransferase: 6 to 50 IU/L
• Bilirubin: 2 to 17 µmol/L
• Direct bilirubin: 0 to 6 µmol/L
• Prothrombin time: 10.9 to 12.5 s
• Albumin: 35 to 50 g/L
• Total protein: 60 to 80 g/L
• Lactate dehydrogenase: 50 to 150 IU/L

Clinical Significance

Liver biochemistries are most useful when treated as part of a clinical process rather than as a stand-alone diagnosis. In everyday practice, these tests help with early case-finding in asymptomatic individuals, orient the differential diagnosis in symptomatic individuals, track disease activity and treatment response, and contribute to severity assessment in established liver disease. In many situations, their real value is practical because they help determine the next step, whether that is repeat testing, medication review, imaging, etiologic workup, fibrosis risk assessment, urgent referral, or interval follow-up.

In asymptomatic individuals, mild abnormalities are common and may be transient, extrahepatic, or clinically insignificant. Nevertheless, mild abnormalities can also represent the first biochemical evidence of chronic liver disease. The clinical task is to distinguish transient variation from persistent pathology without overtesting. Consequently, repeat testing, attention to pattern, and review of alcohol exposure, prescription medications, over-the-counter agents, and supplements remain central to interpretation. A single abnormal result rarely has the same significance as a reproducible abnormal pattern.

Normal liver biochemistry results are clinically reassuring in selected low-risk contexts, as they reduce the likelihood of active hepatocellular injury or clinically significant cholestasis at the time of testing. However, normal liver biochemistry findings should not be treated as a universal rule-out test. In patients with obesity, diabetes mellitus, dyslipidemia, hypertension, substantial alcohol exposure, or other risk factors for chronic liver disease, normal aminotransferase levels do not exclude MASLD, fibrosis, or compensated cirrhosis. Results from recent studies showed high MASLD prevalence among individuals with normal ALT levels and poor performance of ALT alone in detecting steatosis or fibrosis, making this a central point in contemporary interpretation. In high-risk populations, normal enzyme levels may warrant less urgency but do not automatically rule out the risk of liver disease.

When liver biochemistry findings are abnormal, the pattern usually matters more than the absolute value of a single result. A rise driven mainly by AST and ALT levels points toward hepatocellular injury, whereas a disproportionate increase in ALP levels, with or without bilirubin elevation, raises concern for cholestatic disease. Some patients show a mixed pattern, which may reflect overlapping processes or a changing injury pattern over time. Isolated hyperbilirubinemia is a distinct condition and, after fractionation, may suggest hemolysis, inherited bilirubin disorders, or hepatobiliary disease. Looking at the results this way helps narrow the differential diagnosis and prevents common interpretation errors, for example, assuming an isolated ALP level elevation is hepatic before confirming the source or attributing an isolated AST level elevation to liver disease when muscle injury or another extrahepatic condition is the better explanation.

Serial measurements often carry greater clinical significance than isolated values. Trends can help differentiate self-limited disturbances from progressive disease and can detect deterioration before symptoms become obvious. A mild elevation in aminotransferase levels that resolves after discontinuation of a medication or an intercurrent illness has very different implications from a persistent or rising abnormality. Likewise, improving AST and ALT values does not necessarily indicate recovery if the bilirubin level rises or PT/INR worsens. In acute and severe liver injury, trajectory and pattern across the full panel are more informative than aminotransferase magnitude alone.

Bilirubin, albumin, and PT/INR tests become particularly important once the clinical question shifts from etiology to level of severity. Together, these tests help estimate hepatic reserve, identify decompensating disease, and guide the urgency of referral or the need for closer monitoring. Their significance is greatest when interpreted as a group and in a clinical context. For example, in acute liver injury, a rising bilirubin level and worsening PT/INR may signal loss of hepatic reserve and impending liver failure even when aminotransferase levels are falling.

Drug-induced and supplement-induced liver injury remains a high-impact application of liver biochemistries. In many cases, abnormal results are the first objective sign of preventable iatrogenic injury. The clinical significance of these tests in this setting lies not only in detecting injury but also in supporting a structured causal assessment based on exposure timing, biochemical pattern, competing diagnoses, and severity markers such as bilirubin level and INR. This approach is more useful than relying on a single threshold and helps determine when discontinuation, close monitoring, or specialist referral is warranted.

Another major shift in modern practice is that liver biochemistries are increasingly integrated into broader risk-based pathways rather than serving as surrogates for the fibrosis stage. In patients at risk for chronic liver disease, especially those with metabolic risk factors, simple blood-based fibrosis scores and second-line noninvasive tests, such as elastography, are often used to identify clinically important fibrosis, including in patients with normal or minimally abnormal enzyme levels. This changes the clinical significance of the panel: enzymes still matter, but they are one component of a larger risk-stratification strategy.

Terminology also affects clinical reasoning. Referring to these tests as liver biochemistries or liver chemistries is often more accurate than calling them liver function tests, because this terminology clarifies that AST, ALT, ALP, and GGT primarily reflect injury or cholestasis rather than function itself. This language reduces interpretive errors, especially the assumption that normal aminotransferase findings prove normal liver health or that abnormal enzyme results automatically indicate hepatic functional failure.[4][16][18][19][20][28][29][30]

Differential Diagnosis Based on Degree of Aminotransferase Elevation

The magnitude of aminotransferase (ALT and AST) elevation provides an important clinical framework for narrowing the differential diagnosis of liver injury, although it is not diagnostic in isolation and must be interpreted in the clinical context.[30]

Mild elevation (less than 5 times the upper limit of normal)Common causes include MASLD/metabolic dysfunction-associated steatohepatitis, chronic alcohol use, often with an AST to ALT ratio of 2:1 or greater, chronic viral hepatitis infection (hepatitis B or C), and medications (eg, statins, nonsteroidal anti-inflammatory drugs, and antiepileptics). Early hereditary hemochromatosis may also present with mild elevations. Extrahepatic causes such as muscle disorders and thyroid disease should also be considered.

Moderate elevation (5 to 15 times the upper limit of normal)This range is typically seen in acute viral hepatitis infection, early or evolving phases, autoimmune hepatitis, and drug-induced liver injury. Alcoholic hepatitis usually produces mild to moderate elevations, with AST and ALT levels rarely exceeding 300 to 500 IU/L. Clinical context helps distinguish these conditions.

Severe elevation (greater than 15 times the upper limit of normal): Marked elevations are most commonly associated with acute viral hepatitis (hepatitis A, B, or E), severe drug-induced liver injury, toxin-related injury (eg, Amanita phalloides), and ischemic hepatitis, also termed shock liver, due to hypoperfusion. These marked elevations require prompt clinical evaluation. The differential diagnosis remains broad despite the marked increase.

Massive elevation (greater than 10,000 IU/L)Extreme aminotransferase elevations are classically seen in acetaminophen toxicity and profound ischemic injury, for example, following cardiac arrest or severe shock. Rare causes include herpes simplex virus hepatitis infection, particularly in immunocompromised individuals or during pregnancy. Importantly, marked elevation alone does not establish the cause. The degree of aminotransferase elevation does not always correlate with histologic severity or prognosis and should be interpreted in the context of bilirubin level, coagulation parameters, and the overall clinical picture.

Quality Control and Lab Safety

For nonwaived tests, laboratory regulations require, at a minimum, analysis of at least 2 levels of control materials once every 24 hours. Laboratories can assay quality control samples more frequently if deemed necessary to ensure accurate results. Quality control samples should be assayed after analyzer calibration or maintenance to verify proper test performance.

To minimize quality control testing when performing tests for which manufacturers’ recommendations are less frequent than those required by the regulatory agency, such as once per month, laboratories can develop an individualized quality control plan that involves performing a risk assessment of potential sources of error in all phases of testing and putting in place a quality control plan to reduce the likelihood of errors.[31] Westgard multirules are used to evaluate the quality control runs. If any rule is violated, proper corrective and preventive action should be taken before patient testing is performed.

Enhancing Healthcare Team Outcomes

Liver chemistries are one of the most commonly ordered laboratory tests. Mild, isolated elevations in liver chemistries can be considered normal fluctuations and should not trigger expensive and extensive workups. However, clinicians should be aware of various conditions that can lead to elevated liver chemistry results. Thorough history taking and physical examination can provide clues to the differential diagnosis.

Drug and medication history are of utmost importance. The nursing team can help with medication reconciliation. Pharmacists can also assist in identifying potentially hepatotoxic agents. Referral to specialists, such as hepatologists, may be indicated. An interdisciplinary team approach can help identify the underlying etiology with appropriate treatment.[32] This interdisciplinary team paradigm for patient care, employing good record-keeping and open communication lines among different health care disciplines, will result in improved patient care.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Iluz-Freundlich D, Zhang M, Uhanova J, Minuk GY. The relative expression of hepatocellular and cholestatic liver enzymes in adult patients with liver disease. Ann Hepatol. 2020 Mar-Apr;19(2):204-208. [PubMed: 31628070]

2.

Timbrell NE. The Role and Limitations of the Reference Interval Within Clinical Chemistry and Its Reliability for Disease Detection. Br J Biomed Sci. 2024;81:12339. [PMC free article: PMC10932992] [PubMed: 38481978]

3.

Valenti L, Pelusi S, Bianco C, Ceriotti F, Berzuini A, Iogna Prat L, Trotti R, Malvestiti F, D'Ambrosio R, Lampertico P, Colli A, Colombo M, Tsochatzis EA, Fraquelli M, Prati D. Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. Hepatol Commun. 2021 Nov;5(11):1824-1832. [PMC free article: PMC8557310] [PubMed: 34520121]

4.

van Son KC, Te Nijenhuis-Noort LC, Boone SC, Mook-Kanamori DO, Holleboom AG, Roos PR, Lamb HJ, Alblas G, Coenraad MJ, Rosendaal FR, de Mutsert R, Tushuizen ME. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies. Medicine (Baltimore). 2024 Jan 05;103(1):e34934. [PMC free article: PMC10766322] [PubMed: 38181294]

5.

Tapper EB, Lok AS. Use of Liver Imaging and Biopsy in Clinical Practice. N Engl J Med. 2017 Aug 24;377(8):756-768. [PubMed: 28834467]

6.

Gupta M, Choudhury PS, Singh S, Hazarika D. Liver Functional Volumetry by Tc-99m Mebrofenin Hepatobiliary Scintigraphy before Major Liver Resection: A Game Changer. Indian J Nucl Med. 2018 Oct-Dec;33(4):277-283. [PMC free article: PMC6194760] [PubMed: 30386047]

7.

Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018 Aug 14;24(30):3361-3373. [PMC free article: PMC6092580] [PubMed: 30122876]

8.

Langan RC, Hines-Smith KA. Mildly Elevated Liver Transaminase Levels: Causes and Evaluation. Am Fam Physician. 2024 Dec;110(6):585-591. [PubMed: 39700361]

9.

Mijač D, Krstić MN, Marković AP, Popović DD, Krstić JM, Milosavljević T. Abnormal Liver Blood Tests: Primary Care Approach. Dig Dis. 2022;40(2):215-222. [PubMed: 33951646]

10.

Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. World J Hepatol. 2021 Nov 27;13(11):1688-1698. [PMC free article: PMC8637680] [PubMed: 34904038]

11.

Sebode M, Weiler-Normann C, Liwinski T, Schramm C. Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance. Front Immunol. 2018;9:609. [PMC free article: PMC5880919] [PubMed: 29636752]

12.

Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol. 2008 Jun 07;14(21):3374-87. [PMC free article: PMC2716592] [PubMed: 18528935]

13.

Coates P. Liver function tests. Aust Fam Physician. 2011 Mar;40(3):113-5. [PubMed: 21597511]

14.

Scarà S, Bottoni P, Scatena R. CA 19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:247-60. [PubMed: 26530370]

15.

Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014 Apr;6(4):748-73. [PubMed: 24549403]

16.

Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017 Jan;112(1):18-35. [PubMed: 27995906]

17.

Choi J, Jo C, Kim S, Ryu M, Choi WM, Lee D, Shim JH, Kim KM, Lim YS, Lee HC. Updated Reference Intervals for Alanine Aminotransferase in a Metabolically and Histologically Normal Population. Clin Gastroenterol Hepatol. 2024 Nov;22(11):2240-2249.e6. [PubMed: 38750867]

18.

Condon S, Hu H, Kong M, Cave MC, McClain CJ. ALT poorly predicts Nonalcoholic Fatty Liver Disease (NAFLD) and liver fibrosis as determined by vibration-controlled transient elastography in adult National Health and Nutrition Examination Survey 2017-2018. Am J Med Sci. 2024 May;367(5):310-322. [PMC free article: PMC11299156] [PubMed: 38307172]

19.

Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, Navarro V. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023 Mar 01;77(3):1036-1065. [PMC free article: PMC9936988] [PubMed: 35899384]

20.

Hernandez-Tejero M, Clemente-Sanchez A, Bataller R. Spectrum, Screening, and Diagnosis of Alcohol-related Liver Disease. J Clin Exp Hepatol. 2023 Jan-Feb;13(1):75-87. [PMC free article: PMC9840079] [PubMed: 36647416]

21.

Marques-Garcia F, Jung DHH, Pérez SE. Impact of Individualized Hemolysis Management Based on Biological Variation Cut-offs in a Clinical Laboratory. Ann Lab Med. 2022 Mar 01;42(2):169-177. [PMC free article: PMC8548235] [PubMed: 34635610]

22.

Iacovetti G, Collier BB, Rafalko JM, Peevler M, Tokunaga N, Ragar J, Brandon WC, Chappell MR, Grant RP, Sommer GJ, Schaff UY. Assessment of the stability of 20 biochemical analytes in serum and whole blood samples after storage at nonstandard temperatures. Pract Lab Med. 2026 Jan;48:e00514. [PMC free article: PMC12769415] [PubMed: 41503054]

23.

Gowda S, Desai PB, Hull VV, Math AA, Vernekar SN, Kulkarni SS. A review on laboratory liver function tests. Pan Afr Med J. 2009 Nov 22;3:17. [PMC free article: PMC2984286] [PubMed: 21532726]

24.

Ho CKM, Chen C, Setoh JWS, Yap WWT, Hawkins RCW. Optimization of hemolysis, icterus and lipemia interference thresholds for 35 clinical chemistry assays. Pract Lab Med. 2021 May;25:e00232. [PMC free article: PMC8145753] [PubMed: 34095417]

25.

Block DR, Lasho MA, Donato LJ, Meeusen JW. Establishing hemolysis, icterus, and lipemia interference limits for body fluid chemistry analytes measured on the Roche cobas instrument. Am J Clin Pathol. 2024 Oct 03;162(4):356-368. [PubMed: 38709595]

26.

Mainali S, Merrill AE, Krasowski MD. Frequency of icteric interference in clinical chemistry laboratory tests and causes of severe icterus. Pract Lab Med. 2021 Nov;27:e00259. [PMC free article: PMC8567001] [PubMed: 34761095]

27.

Malakouti M, Kataria A, Ali SK, Schenker S. Elevated Liver Enzymes in Asymptomatic Patients - What Should I Do? J Clin Transl Hepatol. 2017 Dec 28;5(4):394-403. [PMC free article: PMC5719197] [PubMed: 29226106]

28.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021 Sep;75(3):659-689. [PubMed: 34166721]

29.

Canivet CM, Costentin C, Irvine KM, Delamarre A, Lannes A, Sturm N, Oberti F, Patel PJ, Decaens T, Irles-Depé M, Fouchard I, Hermabessière P, Roux M, Barthelon J, Calès P, Powell EE, de Ledinghen V, Boursier J. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD. Hepatology. 2023 Mar 01;77(3):920-930. [PubMed: 35822302]

30.

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN., NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023 Dec 01;78(6):1966-1986. [PMC free article: PMC10653297] [PubMed: 37363821]

31.

Lippi G, von Meyer A, Cadamuro J, Simundic AM. Blood sample quality. Diagnosis (Berl). 2019 Mar 26;6(1):25-31. [PubMed: 29794250]

32.

Gurses AP, Xiao Y. A systematic review of the literature on multidisciplinary rounds to design information technology. J Am Med Inform Assoc. 2006 May-Jun;13(3):267-76. [PMC free article: PMC1513658] [PubMed: 16501176]

Disclosure: Prasad Jogu declares no relevant financial relationships with ineligible companies.

Disclosure: Muhammad Zubair declares no relevant financial relationships with ineligible companies.

Disclosure: David Minter declares no relevant financial relationships with ineligible companies.